CLINUVEL Pharmaceuticals (ASX:CUV) has presented new evidence of its lead therapy SCENESSE (afamelanotide) delivering visible and lasting repigmentation in patients with vitiligo, one of the world’s most common pigmentary disorders. …
CLINUVEL’s SCENESSE demonstrates promising results in vitiligo patients
September 21, 2025 Australian Biotech
Latest Video
New Stories
-
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News -
Chemist Warehouse keeps growing as Sigma sets its sights on oral GLP-1s
October 21, 2026 - - Latest News -
America's ever rising GLP-1 curve and how Australia is following
October 21, 2026 - - Latest News -
Patient groups across Asia-Pacific push for a say on medicine prices
October 21, 2026 - - Latest News